HOTAIRM1

Summary

HOTAIRM1 (HOXA transcript antisense RNA, myeloid-specific 1, HGNC:37117) is a long non-coding RNA gene on chromosome 7p15.2.

This non-coding locus is located in the HOX gene cluster. Transcription of this locus is induced by retinoic acid, and transcripts likely function in regulation of myelopoiesis through transcriptional activation of several genes in the HOXA cluster, in addition to several beta-2 integrins.

Source: NCBI Gene 100506311 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:37117
Approved symbol	HOTAIRM1
Name	HOXA transcript antisense RNA, myeloid-specific 1
Location	7p15.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	HOXA-AS1, NCRNA00179, HOXA1-AS1
Ensembl gene	ENSG00000233429
Ensembl biotype	lncRNA
Entrez	100506311
RNAcentral	URS000075CF47 — lncRNA, 1052 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 lncRNA

ENST00000425358, ENST00000428939, ENST00000429611, ENST00000434063, ENST00000495032, ENST00000593300

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000425358 — 3 exons

Exon	Start	End
ENSE00001684197	27099779	27099966
ENSE00001700861	27099074	27099366
ENSE00001797776	27096233	27096388

Expression profiles

Bgee: expression breadth ubiquitous, 130 present calls, max score 98.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.5574 / max 527.8897, expressed in 1457 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77787	5.9366	1259
77786	5.4654	1305
77788	1.1555	654

Top tissues by expression

130 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.29	gold quality
right uterine tube	UBERON:0001302	97.22	gold quality
lower esophagus	UBERON:0013473	96.21	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.20	gold quality
mucosa of stomach	UBERON:0001199	95.89	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.82	gold quality
metanephros cortex	UBERON:0010533	95.72	gold quality
esophagus	UBERON:0001043	95.27	gold quality
spleen	UBERON:0002106	95.22	gold quality
esophagus mucosa	UBERON:0002469	94.95	gold quality
descending thoracic aorta	UBERON:0002345	94.74	gold quality
mucosa of transverse colon	UBERON:0004991	94.40	gold quality
monocyte	CL:0000576	94.33	gold quality
ascending aorta	UBERON:0001496	94.15	gold quality
thoracic aorta	UBERON:0001515	94.06	gold quality
right lung	UBERON:0002167	94.00	gold quality
leukocyte	CL:0000738	93.88	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.10	gold quality
omental fat pad	UBERON:0010414	93.03	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.79	gold quality
thoracic mammary gland	UBERON:0005200	92.68	gold quality
transverse colon	UBERON:0001157	92.40	gold quality
blood	UBERON:0000178	92.08	gold quality
small intestine	UBERON:0002108	91.54	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.94	gold quality
adipose tissue	UBERON:0001013	90.74	gold quality
prostate gland	UBERON:0002367	90.68	gold quality
upper lobe of left lung	UBERON:0008952	90.62	gold quality
intestine	UBERON:0000160	90.61	gold quality
colon	UBERON:0001155	90.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.56

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• HOTAIRM1 plays a role in the myelopoiesis through modulation of gene expression in the HOXA cluster. (PMID:19144990)
• These results indicate that HOTAIRM1 provides a regulatory link in myeloid maturation by modulating integrin-controlled cell cycle progression at the gene expression level. (PMID:24824789)
• The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. (PMID:26436590)
• PU.1 directly activates the expression of HOTAIRM1 through binding to the regulatory region of HOTAIRM1 during granulocytic differentiation. (PMID:27146823)
• Down-regulation of HOTAIRM1 can serve as a biomarker for colorectal cancer. (PMID:27307307)
• Up-regulated expression of HOTAIRM1 could enhance ATRA-induced PML-RARA degradation by affecting autophagic flux and could control myeloid cell differentiation in APL cells. (PMID:27740626)
• HOTAIRM1 contributes to three-dimensional chromatin organization changes required for the temporal collinear activation of HOXA genes. Distinct HOTAIRM1 variants preferentially associate with either UTX/MLL or PRC2 complexes to modulate the levels of activating and silencing marks at the bivalent domain. (PMID:28180285)
• this study illustrates that HOTAIRM1/HOXA1 downregulates the immunosuppressive function of myeloid-derived suppressor celsl and may be a potential therapeutic target in lung cancer. (PMID:29662483)
• HOTAIRM1 is down-regulated in hepatocellular carcinoma tissue, which promotes the apoptosis of hepatocellular carcinoma cells by suppressing the Wnt pathway. (PMID:30070317)
• LncRNA HORAIRM1 suppressed the PI3K/AKT pathway in gastric cancer (GC) and inhibited the progression of GC by serving as a competing endogenous RNA of miR-17-5p, mediating the expression of PTEN. (PMID:30302796)
• Results showed that HOTAIRM1 was up-regulated in glioblastoma multiforme (GBM) with grade malignancy correlation. Further data revealed that HOTAIRM1 was an oncogenic factor that regulated HOXA1 gene expression, promoting tumorigenesis by serving as a scaffold to sequester the chromosome modification enzyme G9a, EZH2 and DNA methyltransferases away from the promoter of HOXA1 gene. (PMID:30376874)
• HOTAIRM1-1 is downregulated in OA cartilages. (PMID:30551410)
• HOTAIRM1 might act as a tumor-suppressor in 5-fluorouracil resistant colorectal cancer cells in vitro and in vivo through downregulating miR-17-5p/BTG3 pathway and inhibiting multi-drug resistance. (PMID:31261026)
• These results show that the lncRNAs PCA3 and HAM-1 are upregulated during thyroid tumor development and progression and may function as oncogenes during tumor progression (PMID:31468286)
• Long non-coding RNA, HOTAIRM1, promotes glioma malignancy by forming a ceRNA network. (PMID:31477638)
• LncRNA HOTAIRM1 promotes osteogenesis by controlling JNK/AP-1 signalling-mediated RUNX2 expression. (PMID:31512358)
• Long Noncoding RNA HOTAIRM1 Maintains Tumorigenicity of Glioblastoma Stem-Like Cells Through Regulation of HOX Gene Expression. (PMID:31691127)
• HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway. (PMID:31862408)
• Over-expression of long noncoding RNA HOTAIRM1 promotes cell proliferation and invasion in human glioblastoma by up-regulating SP1 via sponging miR-137. (PMID:31876683)
• HOTAIRM1 knockdown suppressed the glucose consumption and lactate production, as well as the expression of PFKP in acute myeloid leukemia cells. (PMID:31904363)
• study showed that HOTAIRM1 suppressed ovarian cancer progression through derepression of ARHGAP24 by sponging miR-106a-5p (PMID:31935390)
• Genome-wide screening of functional long noncoding RNAs in the epicardial adipose tissues of atrial fibrillation. (PMID:32147422)
• HOTAIRM1, an enhancer lncRNA, promotes glioma proliferation by regulating long-range chromatin interactions within HOXA cluster genes. (PMID:32180085)
• lncRNA HOTAIRM1 promotes osteogenesis of hDFSCs by epigenetically regulating HOXA2 via DNMT1 in vitro. (PMID:32324272)
• HOTAIRM1 regulates neuronal differentiation by modulating NEUROGENIN 2 and the downstream neurogenic cascade. (PMID:32661334)
• Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis. (PMID:32951513)
• Inactivation of lncRNA HOTAIRM1 caused by histone methyltransferase RIZ1 accelerated the proliferation and invasion of liver cancer. (PMID:32964965)
• Long noncoding RNA HOTAIRM1 promotes myeloid-derived suppressor cell expansion and suppressive functions through up-regulating HOXA1 expression during latent HIV infection. (PMID:33048872)
• Upregulation of HOTAIRM1 increases migration and invasion by glioblastoma cells. (PMID:33323548)
• LncRNA HOTAIRM1 promotes MDSC expansion and suppressive functions through the HOXA1-miR124 axis during HCV infection. (PMID:33328510)
• The function of long noncoding RNA HOTAIRM1 in the progression of prostate cancer cells. (PMID:33368390)
• HOTAIRM1 promotes osteogenic differentiation and alleviates osteoclast differentiation by inactivating the NF-kappaB pathway. (PMID:33404645)
• LncRNA HOTAIRM1 knockdown inhibits cell glycolysis metabolism and tumor progression by miR-498/ABCE1 axis in non-small cell lung cancer. (PMID:33537917)
• lncRNA HOTAIRM1 regulates cell proliferation and the metastasis of thyroid cancer by targeting Wnt10b. (PMID:33650656)
• Investigating function of long noncoding RNA of HOTAIRM1 in progression of SKOV3 ovarian cancer cells. (PMID:33939846)
• The long noncoding RNA HOTAIRM1 controlled by AML1 enhances glucocorticoid resistance by activating RHOA/ROCK1 pathway through suppressing ARHGAP18. (PMID:34262023)
• Developmental Inhibition of Long Intergenic Non-Coding RNA, HOTAIRM1, Impairs Dopamine Neuron Differentiation and Maturation. (PMID:34298885)
• The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. (PMID:34584066)
• Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3. (PMID:34615546)
• IRF4 transcriptionally activate HOTAIRM1, which in turn regulates IRF4 expression, thereby affecting Th9 cell differentiation and involved in allergic rhinitis. (PMID:34929342)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.